Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
After finishing at $2.89 in the prior trading day, RAPT Therapeutics Inc (NASDAQ: RAPT) closed at $1.75, down -39.45%. In other words, the price has decreased by -$39.45 from its previous closing price. On the day, 7.4 million shares were traded. RAPT stock price reached its highest trading level at $1.82 during the session, while it also had its lowest trading level at $1.305.
Ratios:
Our goal is to gain a better understanding of RAPT by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 8.14 and its Current Ratio is at 8.14. In the meantime, Its Debt-to-Equity ratio is 0.05 whereas as Long-Term Debt/Eq ratio is at 0.03.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Piper Sandler on Nov-12-24, Downgraded its rating to Neutral and sets its target price to $2 from $8 previously.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jan 05 ’24 when Brockstedt Dirk G. sold 898 shares for $22.78 per share. The transaction valued at 20,456 led to the insider holds 27,820 shares of the business.
HO WILLIAM sold 2,500 shares of RAPT for $54,200 on Dec 21 ’23. The Chief Medical Officer now owns 15,020 shares after completing the transaction at $21.68 per share. On Nov 28 ’23, another insider, HO WILLIAM, who serves as the Chief Medical Officer of the company, sold 1,500 shares for $13.72 each. As a result, the insider received 20,580 and left with 17,520 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, RAPT now has a Market Capitalization of 61081124 and an Enterprise Value of -48029916.
Stock Price History:
Over the past 52 weeks, RAPT has reached a high of $27.35, while it has fallen to a 52-week low of $1.64. The 50-Day Moving Average of the stock is -11.37%, while the 200-Day Moving Average is calculated to be -71.13%.
Shares Statistics:
The stock has traded on average 297.60K shares per day over the past 3-months and 525760 shares per day over the last 10 days, according to various share statistics. A total of 34.40M shares are outstanding, with a floating share count of 31.00M. Insiders hold about 11.19% of the company’s shares, while institutions hold 82.32% stake in the company. Shares short for RAPT as of 1728950400 were 2866510 with a Short Ratio of 9.63, compared to 1726185600 on 3407623. Therefore, it implies a Short% of Shares Outstanding of 2866510 and a Short% of Float of 11.04.
Earnings Estimates
RAPT Therapeutics Inc (RAPT) is presently subject to a detailed evaluation by 10.0 analysts, each offering their unique perspectives on its market standing.The consensus estimate for the next quarter is -$0.46, with high estimates of -$0.36 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$2.29 and -$2.73 for the fiscal current year, implying an average EPS of -$2.54. EPS for the following year is -$1.89, with 10.0 analysts recommending between -$1.09 and -$2.58.
